Table 6.
Univariate analysis: Influence on OS
| Factor | Median TTP (months) | 95% CI | SE | p = |
|---|---|---|---|---|
| Age > 65 years | 44 vs. 43 | 29.77-58.23 | 7.26 | n.s. |
| 37.75-48.25 | 2.68 | |||
| Age < 35 years | 25 vs. 44 | 7.32-42.68 | 9.02 | 0.023 |
| 38.5-49.5 | 2.81 | |||
| Stage 4 at diagnosis | 43 vs. 39 | 37.74-48.26 | 2.69 | n.s. |
| 25.96-52.04 | 6.66 | |||
| Grading (1,2 versus 3) | 43 vs. 43 | 31.94-54.06 | 5.64 | n.s. |
| 37.38-48.72 | 2.92 | |||
| Histologic type (ductal versus lobular) | 43 vs. 52 | 38.35-47.65 | 2.37 | n.s. |
| 8.41-95.6 | 22.24 | |||
| Positive hormone receptor status | 47 vs. 39 | 38.4-55.61 | 4.39 | 0.075 |
| 31.95-46.05 | 5.6 | |||
| Time to recurrence < 12 months | 46 vs. 42 | 41.52-50.48 | 2.29 | n.s. |
| 35.7-48.3 | 3.21 | |||
| Visceral metastases | 40 vs. 53 | 33.82-46.18 | 3.16 | n.s. |
| 42-62 | 5.1 | |||
| Number of metastatic sites (1 versus 2) | NR* vs. 37 | na§ | na§ | 0.003 |
| 27.35-46.65 | 4.92 | |||
| Number of metastatic sites (2 versus > 2) | 46 vs. 33 | 35.24-56.73 | 5.49 | 0.010 |
| 19.56-46.44 | 6.86 | |||
| Trastuzumab from first-line palliative treatment | 43 vs. 33 | 38.65-47.35 | 2.2 | n.s. |
| 9.02-57.98 | 12.75 | |||
| Response to first-line trastuzumab-based therapy | 46 vs. 42 | 36.33-55.67 | 4.94 | n.s. |
| 34.5-49.5 | 3.82 | |||
| New metastatic sites at progression upon first-line trastuzumab-based therapy | 44 vs. 42 | 26.05-61.96 | 9.16 | n.s. |
| 29.69-54.31 | 6.38 | |||
| Development of brain metastases | 33 vs. 46 | 32.81-43.19 | 2.9 | 0.010 |
| 40.32-51.69 | 5.2 | |||
| Early development of brain metastases | 19 vs. 44 | 9.11-28.89 | 2 | < 0.001 |
| 40.07-47.93 | 5.05 | |||
* NR: Median OS not reached
§ na: Not available